FindTrial
Sign In

Investigation of the factors that affect Aricept medication persistence rate and the safety and efficacy in patients with Alzheimer's Disease in clinical practice

Post-marketing surveillance of donepezil hydrochloride -Investigation of the factors that affect Aricept medication persistence rate and the safety and efficacy in patients with Alzheimer's Disease in clinical practice (Study ART08T)

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1080222138
Enrollment
10000
Registered
2013-07-09
Start date
2013-07-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Interventions

investigational material(s) Generic name etc : Donepezil Hydrochloride(Aricept) INN of investigational material : Therapeutic category code : 119 Other agents affecting central nervous system Dosage

Sponsors

Eisai Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients diagnosed as Alzheimer's Disease and administered Aricept for the first time.

Exclusion criteria

Exclusion criteria: Patients with a history of hypersensitivity to any ingredients of Aricept or piperidine derivatives.

Design outcomes

Primary

MeasureTime frame
Cognitive function MMSE or HDS-R—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026